Comparative Pharmacology
Head-to-head clinical analysis: ALOPRIM versus ULORIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALOPRIM versus ULORIC.
ALOPRIM vs ULORIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Allopurinol inhibits xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine and xanthine to uric acid, thereby reducing serum and urinary uric acid concentrations.
ULORIC (febuxostat) is a xanthine oxidase inhibitor that reduces serum uric acid levels by inhibiting the enzyme xanthine oxidase, which catalyzes the conversion of hypoxanthine to xanthine and xanthine to uric acid.
300 mg orally once daily; may be increased to 600-800 mg/day in divided doses for severe gout.
40 mg orally once daily; may increase to 80 mg once daily if serum uric acid not at target after 2 weeks.
None Documented
None Documented
Allopurinol: 1-2 h; Oxypurinol: 18-30 h (prolonged in renal impairment, up to 7 days in severe CKD)
Terminal elimination half-life is approximately 5-8 hours. This short half-life supports once-daily dosing for maintenance of therapeutic urate-lowering effect.
Renal: ~70% (30% as allopurinol, 40% as oxypurinol); fecal: ~20%; biliary: minor (<5%)
Renal excretion of unchanged drug accounts for approximately 40-45% of the dose. Biliary/fecal excretion eliminates about 50-55% of the dose, primarily as oxidative metabolites.
Category C
Category C
Xanthine Oxidase Inhibitor
Xanthine Oxidase Inhibitor